Ranolazine

證據等級: L5

預測適應症: 1 個

Ranolazine: Original Indication Not Specified — Predicted New Indication: Nephrogenic Syndrome of Inappropriate Antidiuresis

One-Sentence Summary

The current evidence pack does not contain the original approved indication or mechanism of action for Ranolazine (DrugBank ID DB00243). The TxGNN model predicts a possible association with Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but this prediction is currently supported by 0 clinical trials and 0 publications, and the drug is not marketed in the reviewed jurisdiction.

Quick Overview

Item	Content
Original Indication	Not available in current dataset (no recorded indications or licenses)
Predicted New Indication	Nephrogenic Syndrome of Inappropriate Antidiuresis
TxGNN Prediction Score	99.65%
Evidence Level	L5 (model prediction only, no supporting trials/literature)
US Market Status	未上市 (Not Marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Ranolazine in this evidence pack. Additionally, no original approved indication is recorded, which means there is no baseline against which to assess mechanistic or pharmacological similarity between the drug’s known use and the predicted new indication.

Given the absence of both MOA and original-indication data, the predicted link to Nephrogenic Syndrome of Inappropriate Antidiuresis cannot currently be evaluated on mechanistic grounds. The prediction score (99.65%) reflects a statistical association identified within the TxGNN knowledge graph rather than a validated pharmacological rationale. This prediction should be treated as an early-stage computational signal only, pending mechanism-of-action data and independent clinical or literature confirmation.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

US Market Information

Ranolazine currently has no marketing authorization records in the reviewed jurisdiction (market status: 未上市 / Not Marketed; total licenses: 0). No NDA/license entries are available for review.

Safety Considerations

Please refer to the package insert for safety information.

Note: A blocking data gap exists — TFDA label warnings/contraindications for this drug have not yet been retrieved, which prevents completion of the S1 safety pre-assessment for this candidate.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate has no supporting clinical trial or literature evidence (Evidence Level L5, model-prediction only), no mechanism-of-action data, no confirmed original indication, and no current market presence in the reviewed jurisdiction. There is insufficient basis to advance this prediction at this time.

To proceed, the following is needed:

TFDA label warnings/contraindications (blocking gap — required before any safety pre-assessment)
Mechanism of action (MOA) data from DrugBank or equivalent source
Confirmation of Ranolazine’s original approved indication(s)
Independent literature or clinical trial search specifically targeting the drug–disease pair (Ranolazine × NSIAD) to validate or refute the TxGNN signal
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.